房颤患者急性冠脉综合征或经皮冠状动脉介入术后抗栓治疗风险获益权衡:AUGUSTUS研究启示
AUGUSTUS试验事后分析纳入4614例房颤合并近期急性冠脉综合征或经皮冠状动脉介入治疗且使用P2Y12抑制剂的患者,随机接受阿哌沙班或维生素K拮抗剂(VKA)及阿司匹林或安慰剂治疗6个月。结果显示,与VKA相比,阿哌沙班在30天内及30天至6个月出血和缺血风险均较低或相似;阿司匹林在30天内严重出血增加但严重缺血事件减少,30天后严重出血风险仍增加而缺血事件无显著减少。
要点
- 房颤合并近期急性冠脉综合征或经皮冠状动脉介入治疗患者,阿哌沙班优于VKA。
- 阿司匹林使用至30天时,严重出血增加与严重缺血事件减少风险获益相当。
- 30天后继续使用阿司匹林增加出血风险,而无显著缺血事件减少。
核心结论
- 在房颤合并近期急性冠脉综合征或经皮冠状动脉介入治疗且使用P2Y12抑制剂的患者中,阿哌沙班优于VKA。
- 阿司匹林立即使用至30天,严重出血增加与严重缺血事件减少风险获益相当;30天后继续使用阿司匹林增加出血而无显著缺血减少。
研究设计与样本
- AUGUSTUS试验为开放标签、2×2析因随机对照试验,纳入4614例房颤合并近期急性冠脉综合征或经皮冠状动脉介入治疗且使用P2Y12抑制剂的患者,随机接受盲法阿司匹林或安慰剂及开放标签阿哌沙班或VKA治疗6个月。
- 本分析为事后分析,比较随机化至30天及30天至6个月三个复合出血结局和三个复合缺血结局的风险。
主要发现
- 与VKA相比,阿哌沙班在随机化至30天及30天至6个月出血和缺血结局风险均较低或相似。
- 随机化至30天,阿司匹林较安慰剂严重出血绝对风险差0.97%(95%CI 0.23-1.70),严重缺血事件绝对风险差-0.91%(95%CI -1.74至-0.08)。
- 30天至6个月,阿司匹林较安慰剂严重出血绝对风险差1.25%(95%CI 0.23-2.27),严重缺血事件绝对风险差-0.17%(95%CI -1.33至0.98)。
临床怎么用
- 房颤合并近期急性冠脉综合征或经皮冠状动脉介入治疗且使用P2Y12抑制剂的患者,优先选择阿哌沙班而非VKA。
- 阿司匹林使用至30天时出血与缺血风险获益相当,30天后继续使用增加出血而无显著缺血获益,支持个体化决策阿司匹林使用时长。
局限性
- 本分析为事后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In AUGUSTUS (Open-Label, 2×2 Factorial, Randomized, Controlled Clinical Trial to Evaluate the Safety of Apixaban vs Vitamin K Antagonist and Aspirin vs Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention), patients with atrial fibrillation and a recent acute coronary syndrome and those undergoing percutaneous coronary intervention had less bleeding with apixaban than vitamin K antagonist (VKA) and with placebo than aspirin. However, the number of ischemic events was numerically higher with placebo. The aim of this analysis is to assess the tradeoff of risk (bleeding) and benefit (ischemic events) over time with apixaban versus VKA and aspirin versus placebo. METHODS: In AUGUSTUS, 4614 patients with atrial fibrillation and recent acute coronary syndrome or percutaneous coronary intervention on a P2Y12 inhibitor were randomized to blinded aspirin or placebo and to open-label apixaban or VKA for 6 months. In a post hoc analysis, we compared the risk of 3 composite bleeding outcomes and 3 composite ischemic outcomes from randomization through 30 days and from 30 days to 6 months with apixaban and VKA and with aspirin and placebo. RESULTS: Compared with VKA, apixaban had either a lower or a similar risk of bleeding and ischemic outcomes from randomization to 30 days and from 30 days to 6 months. From randomization to 30 days, aspirin caused more severe bleeding (absolute risk difference, 0.97% [95% CI, 0.23-1.70]) and fewer severe ischemic events (absolute risk difference, -0.91% [95% CI, -1.74 to -0.08]) than placebo. From 30 days to 6 months, the risk of severe bleeding was higher with aspirin than placebo (absolute risk difference, 1.25% [95% CI, 0.23-2.27]), whereas the risk of severe ischemic events was similar (absolute risk difference, -0.17% [95% CI, -1.33 to 0.98]). CONCLUSIONS: In patients with atrial fibrillation and recent acute coronary syndrome or percutaneous coronary intervention receiving a P2Y12 inhibitor, apixaban is preferred over VKA. Use of aspirin immediately and for up to 30 days results in an equal tradeoff between an increase in severe bleeding and a reduction in severe ischemic events. After 30 days, aspirin continues to increase bleeding without significantly reducing ischemic events. These results inform shared, patient-centric decision making on the ideal duration of the use of aspirin after an acute coronary syndrome or percutaneous coronary intervention in patients with atrial fibrillation receiving oral anticoagulation. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02415400.
引用
- Alexander JH, Wojdyla D, Vora AN, et al. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS. Circulation. 2020. PMID: 32223444. doi:10.1161/CIRCULATIONAHA.120.046534
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。